Shifting the lines against central nervous system disorders

« Neurological disorders: a major social challenge and a market in crucial need of therapeutic innovation »

> Management

Franck MOUTHON, Chairman and CEO

Franck MOUTHON, Chairman and CEO

Franck Mouthon holds a degree in life sciences from the École Normale Supérieure (ENS-Ulm) and a master's degree in biology from the ENS and Paris VI, VII and XI interuniversity program. He is an alumni of the medical virology program at the Institut Pasteur and participated in the HEC Challenge + entrepreneur program. He has 15 years of experience in team and project management. He joined the Life Sciences Department of the French Alternative Energies and Atomic Energy Commission (CEA) in 1995 where he worked on neurodegenerative diseases at the Institute of Emerging Diseases and Innovative Therapies (IMETI). He has published various papers and filed several patents related to the modulation of drugs targeting neurons. In March 2013, he co-founded Theranexus with Mathieu Charvériat, having obtained the exclusive worldwide rights to the technology they identified at the CEA. He is Chairman of the Board of Directors and Chief Executive Officer. He is also an administrator of France Biotech.

Mathieu CHARVERIAT, Chief Scientific Officer and Deputy CEO

Mathieu CHARVERIAT, Chief Scientific Officer and Deputy CEO

Mathieu Charvériat holds degrees from the École Polytechnique and Mines ParisTech, as well as a PhD in neurosciences and cell biology from the Université Pierre & Marie Curie. He also participated in the HEC Challenge + entrepreneur program with Franck Mouthon. He joined the neurosciences research laboratory of the French Alternative Energies and Atomic Energy Commission (CEA) in 2009, working with Franck Mouthon on prion diseases and non-neuronal cells, where together they published various papers and filed several patents related to the modulation of drugs targeting neurons. In March 2013, he co-founded Theranexus with Franck Mouthon. As part of his duties as Chief Scientific Officer, Mathieu Charvériat is responsible for the company's research teams and scientific partnerships. He is also Deputy CEO and a director.

Julien VEYS, Chief Business Development Officer

Julien VEYS, Chief Business Development Officer

Julien Veys holds a master’s degree in biochemistry and in information and intelligence management from Aix-Marseille University. He has 15 years of experience in the health industry. After working for a contract research organization (CRO), he joined Trophos (a biotech company specialized in neurodegenerative diseases) in 2005, where he held various successive positions, including Chief Business Development Officer, up until the sale of Trophos to Roche Laboratories for €470 million in 2015. He became Chief Business Development Officer of Theranexus in early 2016.

Marie SEBILLE, Chief Medical Officer

Marie SEBILLE, Chief Medical Officer

Marie is an MD by training and holds a PhD in neurosciences. She has almost 30 years of experience in the pharmaceutical industry, where she has worked in various positions as a physician in Global Medical and Global Clinical Development. She contributed to the development of multiple drugs in neurology and psychiatry, then she held several executive positions managing Clinical Operations in Sanofi R&D. During her tenure, Marie’s organization supported all major registration files in Rare Diseases, Oncology, I&I and Diabetes & Metabolism, as well as Life Cycle Management programs.  Marie joined Theranexus in 2021 as Chief Medical Officer.

Thierry LAMBERT, Chief Financial Officer

Thierry LAMBERT, Chief Financial Officer

Thierry Lambert holds a degree in business administration from Birmingham University and an MBA from INSEAD. He is also a qualified chartered accountant and ICAEW-certified statutory auditor (Institute of Chartered Accountants in England and Wales). He worked for five years at PwC and four years in syndicated and corporate finance before being successively appointed as Chief Financial Officer for listed companies Naturex (specialized in ingredients for the health and food industries) and Safe Orthopaedics (specialized in spinal implants). He became Chief Financial Officer of Theranexus in 2017.